# A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

> **NCT01527305** · PHASE4 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 212 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone palmitate

## Key facts

- **NCT ID:** NCT01527305
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-22
- **Primary completion:** 2013-12-31
- **Final completion:** 2013-12-31
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527305, "A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT01527305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*